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Abstract
Signaling lymphocyte activation molecule (SLAM), a glycoprotein expressed on activated lymphocytes and antigen-presenting cells, has been shown to be a coregulator of antigen-driven T
cell responses and is one of the two receptors for measles virus. Here we show that T cell receptor–
induced interleukin (IL)-4 secretion by SLAM/ CD4 cells is down-regulated, whereas interferon
 production by CD4 T cells is only slightly up-regulated. Although SLAM controls production
of IL-12, tumor necrosis factor, and nitric oxide in response to lipopolysaccharide (LPS) by
macrophages, SLAM does not regulate phagocytosis and responses to peptidoglycan or CpG.
Thus, SLAM acts as a coreceptor that regulates signals transduced by the major LPS receptor
Toll-like receptor 4 on the surface of mouse macrophages. A defective macrophage function
resulted in an inability of SLAM/ C57Bl/6 mice to remove the parasite Leishmania major. We
conclude that the coreceptor SLAM plays a central role at the interface of acquired and innate
immune responses.
Key words: SLAM • macrophage • T cell • L. major

Introduction
The self-ligand glycoprotein, signaling lymphocyte activation
molecule (SLAM or CD150), is not only found on the surface
of activated and memory T cells, but also on the surface of
activated B cells, dendritic cells, and macrophages (1). SLAM
is thought to play an important role in adhesion between T
cells and APCs and has been shown to act as a coreceptor
in TCR-dependent responses (1, 2). SLAM, together with
CD46, is one of the two receptors for measles virus (3).
In T cells, SLAM-initiated signal transduction is in part
controlled by SLAM-associated protein (SAP or SH2D1A;
reference 4). SAP is a single SH2 domain protein adaptor
that binds to specific tyrosine motifs on the cytoplasmic
tail of SLAM and five SLAM-related receptors (CD84,
CD229, CD244, NTB-A, and CS1; reference 2). As an
adaptor, SAP recruits Fyn, which in turn induces tyrosine
phosphorylation of the SLAM receptors and subsequently
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Address correspondence to Cox Terhorst, Division of Immunology,
RE-204, Beth Israel Deaconess Medical Center, Harvard Medical
School, 41 Avenue Louis Pasteur, Boston, MA 02215. Phone: (617) 6677147; Fax: (617) 667-7140; email: terhorst@bidmc.harvard.edu
A. Satoskar’s present address is Department of Microbiology, Ohio
State University, 484 West 12th Ave., Columbus, OH 43210.

1255

recruits a set of signaling molecules that includes SHP, Shc,
Dok1/2, and RasGap (5–7). EAT-2, which is structurally
related to SAP, may have a similar function in APCs (2).
An important function in immunobiology was attributed
to SLAM and related receptors because mutations in SAP
cause a severe immunodeficiency termed X-linked lymphoproliferative syndrome (2, 4, 8). SAP mutations in X-linked
lymphoproliferative syndrome result in three major disease
manifestations: fulminant infectious mononucleosis, B cell
lymphomas, and dys-gammaglobulinemia (2). TCR-induced
IL-4 production is impaired in SAP/ T cells (9, 10), as
judged by in vivo and in vitro experiments. SAP/ mice
are also hyperresponsive to infection with the lymphocytic
choriomeningitis virus with increased numbers of IFN-–
producing cells observed in the spleen and liver (9, 10).
Because SAP partakes in signal transduction initiated by
six SLAM family members in T cells, we hypothesize that
the diverse outcomes of a SAP mutation are the consequences of a combination of contributions of SLAM-like
Abbreviations used in this paper: ES, embryonic stem; NO, nitric oxide;
SAP, signaling lymphocyte activation molecule–associated protein; SLAM,
signaling lymphocyte activation molecule; TLR, Toll-like receptor.

J. Exp. Med.  The Rockefeller University Press • 0022-1007/2004/05/1255/10 $8.00
Volume 199, Number 9, May 3, 2004 1255–1264
http://www.jem.org/cgi/doi/10.1084/jem.20031835

receptors. To dissect the individual contribution of SLAM
signaling to immune responses, we generated a mouse that
is defective in SLAM. Here we show that SLAM, like SAP
(9, 10), is involved in the regulation of Th2 development.
In contrast to the SAP/ C57BL/6 mice, SLAM/
C57BL/6 mice also have impaired macrophage functions
and consequently a defective immune response to infection
with the parasite Leishmania major.

Materials and Methods
Generation of SLAM-deficient Mice. A targeting construct was
constructed from a 129/Sv mouse pBAC clone (11) and was
placed into the plasmid vector pPNT, which includes a thymidine kinase gene expressed from the PGK promoter (PGK-tk) for
positive selection. The second and third exons of the SLAM
gene, IgV and IgC, encoding the complete ectodomain of
SLAM, were replaced with the neomycin-resistance gene (Neo).
An 8.2- and a 3.8-kb genomic DNA fragment flank the neomycin-resistance gene.
The targeting vector was linearized at a unique NotI site and
electroporated into J1 embryonic stem (ES) cells (9). G418 and
FIAU-resistant ES cell colonies were screened using Southern
blot analysis. KpnI digestion of genomic DNA generated a 13-kb
band from the endogenous WT SLAM allele, whereas the correctly targeted SLAM allele generated an additional 8.8-kb band
(see Figs. 1, A and B). The single integration site was confirmed
with the internal 5 probe upon SacI digestion of the DNA (unpublished data). A SLAM/ ES cell clone was injected into
C57BL/6 and BALB/c blastocysts. Chimeric mice were bred
into the appropriate background. F1 mice with germline transmission of SLAM/ F1 mice (129/Sv  BALB/c or 129/Sv 
C57Bl/6) were bred to homozygocity. SLAM / mice were
backcrossed with WT BALB/c or C57Bl/6 mice six times and
were kept under specific pathogen-free conditions.
RT-PCR. RT-PCR was performed as previously described
(11) using a 5 UT forward primer encoding the signal peptide in
the first exon, 5-GATCCCAAAGGATCCCTTTCCTGG-3 ,
and a reverse primer derived from the last exon CP3, 5 -GGTCCAGTTCAGTGTGGATTTTGG-3 , defining a 1.1-kb product containing full-length SLAM cDNA (see Fig. 1 C).
Mice. SAP/ C57BL/6 mice (9), SLAM/ BALB/c and
SLAM / C57BL/6 mice, and TCR transgenic DO11.10
BALB/c mice (12) were kept under specific pathogen-free conditions. SAP/  DO11.10 BALB/c mice and SLAM / 
DO11.10 BALB/c mice were generated by crossing mice that
were homozygous for each mutation until double homozygocity
was reached. This was judged by the appropriate PCR reactions
(9 and this paper) or by staining with monoclonal antibody KJ126 that detects the  TCR, which is expressed on the surface
of the OVA-specific CD4  cells of DO11.10 (12).
Flow Cytometry. Surface staining analysis was performed as
previously described (13, 14). In brief, cells were suspended at
5  106 cells/ml in PBS. Anti-mSLAM (9D1) was used at 10 g/
ml and detected with 10 g/ml biotin-conjugated goat polyclonal anti–rat Ig (BD Biosciences), followed by 1 g/ml streptavidin-conjugated Red 670 (Invitrogen).
For cytoplasmic staining of IFN-  production, splenic T cells
were resuspended at 106/ml and stimulated with 5 g/ml platebound anti-CD3 for 3 d. 2 h before harvesting, 1 g/ml Brefeldin A was added to the cultures. Cells were stained with
FITC-conjugated anti-CD4 or biotin-conjugated anti-CD8 (BD
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Biosciences) for 30 min at 4 C in a balanced salt solution supplemented with1% FCS. Cells were then washed twice in buffered
saline before fixation in buffered saline/4% paraformaldehyde for
10 min at room temperature. After fixation, cells were washed
twice with balanced salt solution/1% FCS and resuspended in
permeabilization buffer (PBS, 0.1% saponin, and 1% FCS) containing anti–IFN- monoclonal antibody (BD Biosciences) for 30
min. The percentage of cells expressing cytoplasmic IFN-  was
determined by flow cytometry.
ELISA Assays for Cytokine Secretion. All cytokine ELISA kits
were obtained from BD Biosciences. Tissue culture supernatants
were stored at 80 C until analysis. ELISA assays were performed according to the manufacturer’s instructions. Standard
curves were generated using known amounts of purified murine
rIL-4, rIL-6, rIL-12p40, rIL-12p70, or TNF-  (BD Biosciences).
In Vitro T Cell Assays. CD4 cells were purified using negative selection columns (9) cultured with 5 g/ml anti-CD3 antibody (2C11)–coated plates and 5 g/ml soluble anti-CD28 or
with a combination of 10 ng/ml PMA and 1 M ionomycin in
the presence of 10 ng/ml recombinant IL-2 (BD Biosciences) for
72 h. Supernatants were analyzed for IL-4 or IFN-  by ELISA as
previously described (9). IFN-  production was determined by
cytoplasmic staining and by flow cytometry as previously described (9).
In Th1- or Th2-polarized experiments, exogenous cytokines
or anti-cytokine antibodies were added to the anti-CD3 and antiCD28 antibody, as indicated. Th2 cell differentiation was promoted in the presence of 100 ng/ml IL-4 and 10 g/ml anti–IL12 antibody, and Th1 differentiation was promoted by 10 g/ml
anti–IL-4 antibody and 1 ng/ml IL-12 (all from BD Biosciences).
After the cells were cultured for 4 d, they were washed and resuspended at 106 cells/ml. The secondary culture used only platebound anti-CD3 and lasted for 24 h. As described above, 10 ng/
ml IL-2 (BD Biosciences) was added to all cultures (9).
For IL-4 and IFN- secretion by CD4 T cells isolated from
SLAM/  DO11.10 or DO11.10 mice, the percentage of KJ126 CD4 cells from each mouse was determined by flow cytometry using KJ-126 FITC (Caltag) and CD4-PE (BD Biosciences). Equal numbers of KJ-126  CD4 cells were plated in
complete media at 2  105 cells/well in a 24-well plate for 3 d in
the presence of 2  106 APCs and 1.0 g of an OVA peptide,
OVA 323–339. Surface staining analysis was performed with
anti–mouse SLAM (9D1) as previously described (13). Secondary
stimulations were performed for 24 h under the same conditions.
IL-4 and IFN- secretion was determined at day 3 of the primary
stimulation and 24 h after the secondary stimulation by ELISA.
Cytokine Production by In Vitro–stimulated Macrophages. Resting or thioglycollate-elicited macrophages were obtained by peritoneal lavage as previously described (13). Macrophages were
stimulated in a medium containing 2 ng/ml LPS, 200 U/ml IFN- ,
2 ng/ml LPS plus 200 U/ml IFN- , and 10 M CpG or 25 g/
ml peptidoglycan.
In other experiments, 2  106 macrophages were activated
with increasing amounts of LPS (1, 10, or 100 ng/ml). After the
cells were incubated for 24 h, supernatants were assayed for IL12p70, IL-12p40, TFN-, or IL-6 by ELISA (BD Biosciences).
For antibody stimulation of macrophages, cells were cultured
for 24 h with rat anti–mouse SLAM (9D1) at concentrations
ranging between 0 to 10 g/ml in the presence of blocking Fc
fragments (13). To each well, a rat anti–mouse IgG1 isotype control antibody was added (BD Biosciences) in a concentration
range from 10 to 0 g/ml resulting in a final concentration of 10
g/ml Ig at each experimental point.
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Nitric oxide (NO) production was quantified by the accumulation of nitrite (as a stable end product) in the supernatants by
the standard Griess reaction as previously described (15). In brief,
50 l of the supernatants was removed from 24-well plates and
incubated with an equal volume of Griess reagent (1% sulfanilamide/0.1% naphthalene diamine dihydrocloride/2.5% H 3PO4)
at room temperature for 10 min. The absorbance at 570 nm was
determined with a microplate reader. Conversion of absorbance
to micromolar concentration of NO was deduced from a standard curve using a known concentration of NaNO 2 diluted in
DMEM medium. All determinations were performed in quadruplicate and expressed as micromolar concentration of NO.
Antigen Presentation by Macrophages. To quantify the in vitro
proliferative response to OVA peptide, thioglycollate-elicited
macrophages (2  105/well) from SLAM / or SLAM /
mice were cocultured with KJ-126  CD4 splenic T cells from
DO11.10 mice (105/well) in DMEM medium supplemented
with 2 mM l-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FCS for 3 d. OVA peptide was added at the
indicated concentrations (from 0.01 to 1.0 g/ml). The cells
were cultured for 72 h and [ 3H]TdR (1 Ci /well) was added for
the last 18 h of the assay. The cells were harvested onto filters using an automated cell harvester.
Phagocytosis of Escherichia coli F18 by Macrophages. After macrophages were plated at 10 6 cells/ml E. coli, F18 bacteria were
added to the culture media at a concentration of 10 7 bacteria/ml.
After 1 h incubation at 37 C, the cells were washed three times
with PBS and lysed using 1% Triton in H 2O for 10 min at 4 C.
Dilutions of the lysate were streaked onto LB plates and incubated for 24 h. Phagocytosis rates were obtained by counting colonies after 24 h (16, 17).
Infection with L. major. Mice were infected subcutaneously
into one hind footpad with 2  106 L. major stationary phase promastigotes in a final volume of 50 l as previously described (18).
The development of lesions was monitored with a vernier cali-

per, measuring increase in footpad thickness compared with the
uninfected footpad. To determine parasite loads, infected mice
were killed and their footpads were collected and homogenized.
The number of amastigotes in each footpad was counted with a
Nuebaer hemocytometer. Data are expressed as mean
SEM
number of amastigotes per footpad. Leishmaniacidal activity was
determined as previously described (18–20).
T Cell Assays after Infection with L. major. The draining inguinal lymph nodes from mice infected with L. major were removed aseptically and cell suspensions were prepared, as previously described (18–20). 100 l aliquots containing 3  105
lymph node cells in complete RPMI medium were added in triplicate to the wells of 96-well flat-bottomed tissue culture plates
containing 20 g/ml soluble L. major antigen per well in different
concentrations (18–20). After incubation at 37 C in 5% CO2 for
60 h, 100 l of the culture supernatant was removed from each
well and stored at 70 C for cytokine assays and replaced with
100 l complete medium containing the appropriate Ci of tritiated thymidine. After an additional 12 h of incubation at 37 C, it
was harvested onto filter paper with a cell harvester. Thymidine
uptake was measured by liquid scintillation using a  counter
with 1 ml Optiscint added to the filter discs in vials and counted
for 5 min each. The stimulation index values at the end of the L.
major infection were calculated as the quotient of antigen stimulated/unstimulated cells.
Online Supplemental Material. Results of experiments, which
complement the data presented in the paper, are shown in Figs.
S1–S6. In Fig. S1, IL-4 and IFN- secretion by resting and
anti-CD3/CD28 activated SLAM / C57BL/6 and SLAM/
BALB/c T cells. In Fig. S2, IL-4 and IFN- secretion by resting
and anti-CD3/CD28 activated CD4  cells purified from the
spleens of SLAM/ BALB/c mice. Secretion of IL-4 and IFN-
by SLAM/ C57BL/6 and WT C57BL/6 CD4  cells cultured
under Th1- and Th2-polarizing conditions is shown in Fig. S3.
In Fig. S4, secretion of IL-4 and IFN- by SLAM/ BALB/c

Figure 1. Targeted disruption of the mouse
SLAM gene. (A) The targeting vector. Configuration of the WT SLAM genomic locus, the
targeting vector, and the chromosomal locus
after homologous recombination with the targeting vector is shown. The second and third
exons of the SLAM gene, IgV and IgC, encoding the complete ectodomain of SLAM, were
replaced with the neomycin resistance gene
(Neo). An 8.2- and a 3.8-kb genomic DNA
fragment flank the neomycin resistance gene.
The locations of the two probes used in the
Southern blotting analysis are shown. SP, signal
peptide; TM, transmembrane region; CP1,
CP2, and CP3, cytoplasmic domains; S, SacII;
K, KpnI. (B) Southern blot analysis. Screening
for homologous recombination events by Southern blotting of tail DNA samples used the 3
probe in conjunction with a KpnI (K) digest. A
13-kb band is detected in WT and heterozygote mice. An 8.8-kb band, which results from
a new KpnI site in the targeting vector, is detected in heterozygotes (/) and homozygotes (/). (C) RT-PCR analysis. RT-PCR
products were generated with RNA from the
thymus or spleen of SLAM/ or SLAM/
mice. Although an SP plus CP3 primer pair detects a 1.1-kb RT-PCR product in SLAM/ thymocytes (T) or splenocytes (S), no RT-PCR product is
detected in the thymus or spleen of SLAM/ mice. (D) Absence of SLAM surface expression in SLAM-deficient thymocytes. SLAM/ or SLAM/
thymocytes were stained with a monoclonal rat anti–mouse SLAM antibody (9D1) and analyzed by flow cytometry.
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and WT BALB/c CD4  cells cultured under Th1- and Th2polarizing conditions is shown. In Fig. S5, T cell receptor–mediated Ca2 entry in CD4 T cells of WT SLAM/ and SAP/
C57BL/6 mice is identical. Altered IL-12, TNF-, IL-6, and
NO production by peritoneal macrophages from SLAM /
BALB/c mice is shown in Fig. S6. Figs. S1–S6 are available at
http://www.jem.org/cgi/content/full/jem.20031835/DC1.

Results

Figure 2. Deviation of cytokine production by CD4 and CD8
SLAM/ T cells. (A) IL-4 secretion by CD4 cells purified from
SLAM/ or SLAM/ C57BL/6 mice. SLAM/ or SLAM/ C57BL/6
CD4 cells were purified using negative selection columns. In the primary
stimulation (1 ) CD4 cells were stimulated with 5 g/ml anti-CD3
antibody (2C11)–coated plates and 5 g/ml soluble anti-CD28, or with a
combination of 10 ng/ml PMA and 1 M ionomycin in the presence of
10 ng/ml recombinant IL-2 (BD Biosciences; P/I) for 72 h. IL-4 in the
cell culture supernatants was determined by ELISA. (B) IFN- secretion
by CD4 cells purified from SLAM/ or SLAM/ C57BL/6 mice.
SLAM/ or SLAM/ C57BL/6 CD4 cells were purified using negative
selection columns. CD4 cells were stimulated as described in A and
IFN- in the cell culture supernatants was determined by ELISA. (C) Impaired IL-4 secretion by SLAM/  DO11.10 CD4 and SAP/ 
DO11.10 CD4 cells upon stimulation with APCs and OVA peptide. IL-4
secretion after primary (1 ) and secondary (2 ) stimulation of
CD4 T cells isolated from SLAM/  DO11.10, SAP/  DO11.10,
or DO11.10 TCR transgenic mice were determined. Equal numbers of
purified KJ-126/CD4 T cells isolated from SLAM/  DO11.10,
SAP/  DO11.10, or DO11.10 TCR transgenic BALB/c mice (2  105
cells/well) were stimulated for 3 d with APCs (2  106) pulsed with 1.0
of the OVA peptide OVA 323–339. Secondary stimulations were performed for 24 h under the same conditions. IL-4 secretion was determined at day 3 of the primary stimulation and 24 h after the secondary
stimulation by ELISA. (D) IFN- secretion by SLAM/  DO11.10
CD4 and SAP/  DO11.10 CD4 cells upon stimulation with APCs
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Deviation of Cytokine Production by SLAM/ CD4 and
CD8 T Cells. A mouse with a targeted disruption of the
second and third exon of the SLAM gene was generated by
homologous recombination in ES cells (Fig. 1, A and B).
SLAM-deficient mice were fertile, morphologically indistinguishable from WT littermates, and no defects in their
T, B, or NK cell development were detected by cell surface marker analyses. No SLAM mRNA was detected in
mice that were homozygous for the gene defect (Fig. 1 C)
and SLAM-deficient thymocytes, which are the highest
SLAM expressors in WT mice, do not stain with the anti–
mouse SLAM antibody 9D1 (Fig. 1 D).
To determine whether SLAM/ CD4 T cells deviated
in their cytokine production along the lines of SAP/ T
cells, several in vitro assays were performed. First, total T
cells purified from the spleen of SLAM/ C57BL/6 and
WT C57BL/6 mice were triggered with a combination of
anti-CD3 and anti-CD28. Production of IFN- was then
measured by cytoplasmic staining and cytofluorimetric
analyses using anti-CD8 and anti-CD4 antibodies. Although SLAM/ CD8 T cells produce more IFN- than
WT C57BL/6 CD8 T cells, this difference is less dramatic
in CD4 cells (unpublished data). A modest increased
IFN- secretion by T cells was found by ELISA, regardless of the genetic background (Fig. S1, B and D, which is
available at http://www.jem.org/cgi/content/full/jem.
20031835/DC1). Stimulation of total T cells from either
SLAM/ C57BL/6 or SLAM/ BALB/c mice with antiCD3 alone or with a combination of anti-CD3 and antiCD28, also resulted in a reduced production of IL-4, presumably by CD4 cells (Fig. S1, A and C).
Indeed, purified CD4 cells isolated from SLAM/
C57BL/6 mice activated with a combination of anti-CD3
and anti-CD28 secreted reduced amounts of IL-4 in a primary stimulation compared to WT C57BL/6 CD4 cells
(Fig. 2 A). Using the same stimulation conditions, we
consistently observed a slight increase in IFN- secretion
by SLAM/ C57BL/6 CD4 cells versus WT C57BL/6
CD4 cells (Fig. 2 B). Upon primary or secondary stimulation with anti-CD3 and anti-CD28, CD4 cells from puriand OVA peptide. Cells described in C were analyzed for IFN- by
ELISA after primary (1 ) and secondary (2 ) stimulation. (E) Transcription of IL-4 and IFN- in NKT cells after anti-CD3 administration.
RT-PCR products of IL-4, IFN-, and GAPDH were generated with
spleen RNA samples isolated from anti-CD3 or PBS-injected mice.
SLAM/ C67BL/6 and WT C67BL/6 littermates as well as SLAM/
BALB/c and WT BALB/c were used. The RT-PCR products were analyzed on a 1% agarose gel and visualized by UV light.
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fied SLAM/ BALB/c mice also produced less IL-4 than
their WT counterparts (Fig. S2, which is available at
http://www.jem.org/cgi/content/full/jem.20031835/DC1).
However, when polarizing Th2 conditions were used,
SLAM/ C57BL/6 and WT C57BL/6 CD4 cells secreted comparable amounts of IL-4 (Fig. S3, which is
available at http://www.jem.org/cgi/content/full/jem.
20031835/DC1). Using polarizing Th2 conditions in the
second stimulation, SLAM/ BALB/c and WT BALB/c
CD4 cells also secreted comparable amounts of IL-4 (Fig.

S4, which is available at http://www.jem.org/cgi/content/
full/jem.20031835/DC1). The IFN- production remained slightly higher when the cells were cultured under
Th1-polarizing conditions (Figs. S3 and S4). Taken
together, these results were indicative of an impaired production of IL-4 by CD4 cells purified from SLAM/
C57BL/6 and SLAM/ BALB/c mice in primary and secondary stimulations. However, IL-4 secretion by purified
CD4 cells readily reaches a WT level in the presence of
IL-4. These SLAM/ C57BL/6 and SLAM/ BALB/c

Figure 3. Altered IL-12, TNF-, IL-6, and NO production by peritoneal macrophages from SLAM/
C57BL/6 mice. (A) IL-12 production by SLAM/
C57BL/6 or WT SLAM/ C57BL/6 peritoneal macrophages. Resting peritoneal macrophages from 12 SLAM 
C57BL/6 or WT SLAM  C57BL/6 mice were stimulated with 200 U/ml IFN-, 2 ng/ml LPS, or with IFN-
plus LPS for 24 h. IL-12p70 was determined by ELISA as
described in Materials and Methods. M, cells incubated in
medium only. (B) TNF- production by SLAM/
C57BL/6 or WT SLAM/ C57BL/6 peritoneal macrophages. Resting peritoneal macrophages from SLAM 
C57BL/6 or WT SLAM  C57BL/6 mice were stimulated as described in A. TNF- was determined by ELISA
in the same culture supernatants as described in Materials
and Methods. M, cells incubated in medium only. (C) IL-6
production by SLAM/ C57BL/6 or WT SLAM/
C57BL/6 peritoneal macrophages. Resting peritoneal
macrophages from SLAM  C57BL/6 or WT SLAM 
C57BL/6 mice were stimulated as described in A. IL-6
was determined by ELISA in the same culture supernatants
as described in Materials and Methods. M, cells incubated
in medium only. (D) NO production by SLAM/
C57BL/6 or WT SLAM/ C57BL/6 peritoneal macrophages. Resting peritoneal macrophages from SLAM 
C57BL/6 or WT SLAM  C57BL/6 mice were stimulated as described in A. NO was determined in the same
culture supernatants as described in Materials and Methods.
M, cells incubated in medium only. (E) IL-12p40 production
is impaired in thioglycollate-induced peritoneal macrophages
from SLAM/ C57BL/6 mice, but not from SAP/
C57BL/6 mice. Thioglycollate-elicited macrophages were
isolated from the peritoneal cavity of SLAM/, SAP/,
or WT SLAM/ C57BL/6 mice. 2  106 macrophages
were activated with increasing amounts of LPS (at 1, 10, or
100 ng/ml). Supernatants were collected after 24 h and
IL-12p40 was determined by ELISA. (F) IL-12p40 production by macrophages in response to CpG and PGN.
Thioglycollate-elicited peritoneal SLAM/ or SLAM/
BALB/c macrophages (106 per well) were treated with 10
M CpG or 25 g/ml peptidoglycan for 24 h. Supernatants were removed and IL-12p40 levels were determined
by ELISA. (G) TNF- production by macrophages in response to CpG and PGN. Thioglycollate-elicited peritoneal
SLAM/ or SLAM/ BALB/c macrophages (106 per
well) were treated with 10 M CpG or 25 g/ml peptidoglycan for 24 h. Supernatants were used to determine
IL-12p40 levels by ELISA. (H) Antigen presentation by
macrophages. 2  105 thioglycollate-elicited peritoneal
SLAM/ or SLAM/ BALB/c macrophages were pulsed
with 0.01–1 g/ml of the OVA peptide OVA 323–339.
Next, antigen-pulsed macrophages were incubated for 3 d
with 105 KJ126 CD4 T cells isolated from DO11.10 TCR transgenic mice. To determine DNA synthesis, cultures were pulsed with [3H]thymidine in
the final 18 h. (I) Phagocytosis of F18 E. coli by macrophages. Thioglycollate-elicited peritoneal SLAM/ or SLAM/ BALB/c macrophages were
incubated with E. coli F18 bacteria. After 1 h, cells were lysed and phagocytosis rates were obtained by counting colonies after 24 h of incubation. CFU,
colony-forming units.
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CD4 cells also consistently produce more IFN- than WT
cells. As in SAP/ mice, the increase in IFN- production
by SLAM/ CD8 cells appears more robust than that of
SLAM/ CD4 cells.
Because the results obtained with SLAM/ mice indicated impaired development of Th2 cells and were similar
to those previously observed with SAP/ CD4 cells (9,
10), we compared the antigen responses of SLAM/
CD4 cells and SAP/ CD4 cells. Reduced levels of IL-4
secretion were detected after triggering of both SLAM/
DO11.10 CD4 cells (KJ-126 cells) or SAP/ DO11.10
CD4 cells (KJ-126 cells) with OVA peptide–pulsed
APCs (Fig. 2 C). The defect in IL-4 secretion by SLAM/
KJ-126/CD4 cells was less robust than that of SAP/
KJ-126/CD4 cells because after a secondary stimulation
with antigen-pulsed APCs, WT levels of IL-4 secretion were
detected (Fig. 2 C). IFN- secretion by either SLAM/ or
SAP/ DO11.10 CD4 cells was similar to that by WT
BALB/c DO11.10 CD4 cells (Fig. 2 D).
It is well established that shortly after injection of WT
mice with anti-CD3, large amounts of IL-4, IFN-, and
other key cytokines are produced immediately by NKT
cells (21, 22). To test whether IL-4 gene activation was defective in SLAM/ NKT cells, SLAM/ BALB/c and
SLAM/ C57BL/6 mice were injected intravenously with
anti-CD3 and cytokine mRNA levels were analyzed 90
min after injection by RT-PCR. As shown in Fig. 2 E, IL-4
and IFN- mRNA levels in SLAM-deficient NKT cells
were indistinguishable from those of the corresponding
WT mice, regardless of the strain background.
Taken together, the data indicate that the coreceptor
SLAM positively regulates TCR-induced IL-4 production
by naive and activated CD4 T cells, but not by NKT cells.
By contrast, SLAM signals negatively interfere with TCRinduced IFN- secretion by CD8 and to a lesser extent by
CD4 cells.
The SLAM-induced signals that are involved in coactivation of the IL-4 gene are as yet unknown. Signal transduction by SLAM is in part governed by SAP, which is an adaptor that links the src kinase FynT to the SLAM receptor. SAP
appears to bind to the SH3 domain of FynT and it therefore
directly couples FynT to SLAM (6, 7). Thus, triggering of
the SLAM receptor by anti-SLAM induces SAP-dependent
tyrosine phosphorylation of a number of targets, including

SHIP, Dok1, Dok2, and RasGAP (5). The SLAM/SAP signal transduction pathway that interferes with TCR-induced
activation of the IL-4 gene in CD4 cells does not involve
Ca2-dependent mechanisms, as judged by single cell Ca2
influx experiments (Fig. S5, which is available at http://
www.jem.org/cgi/content/full/jem.20031835/DC1).
Impaired Responses to LPS by SLAM/ Macrophages.
Because SLAM is also expressed on activated macrophages
(13, 23), we examined whether SLAM controls macrophage functions. To this end, purified resting peritoneal
macrophages were stimulated with LPS, IFN-, or with a
combination of LPS and IFN-. As shown in Fig. 3, A and
B, the levels of secreted TNF- and IL-12 by activated
SLAM/ C57BL/6 macrophages are reduced when compared with those of WT mice. Similarly, NO production
was impaired in LPS/IFN-–stimulated SLAM/ C57BL/6
macrophages (Fig. 3 C). By contrast, LPS-stimulated
SLAM/ macrophages secrete IL-6 at levels that are
higher than WT levels (Fig. 3 D).
Using purified resting peritoneal macrophages from
SLAM/ BALB/c mice, the same results were obtained
(Fig. S6, which is available at http://www.jem.org/
cgi/content/full/jem.20031835/DC1). Importantly, when
macrophages from the peritoneal cavity of thioglycollatetreated SLAM/ BALB/c mice were stimulated with LPS,
a low level of IL-12 secretion was again detected (Fig. 3 E).
This result indicates that the impaired cytokine production
is not dependent upon the method of isolation of the macrophages. As expected from the absence of SAP in macrophages (4, 8), SAP/ BALB/c (Fig. 3 E) macrophages did
not display a defect in IL-12 production.
The possibility that SLAM/ peritoneal cavity macrophages lack one of the members of the known LPS receptor complex, i.e., Toll-like receptor (TLR)-4/MD-2 and
CD14, or the IFN- receptor, was excluded by FACS®
analyses (unpublished data). Importantly, when SLAM/
macrophages were stimulated with CpG or peptidoglycan,
TNF secretion was comparable to that of WT macrophages
(Fig. 3 F). Thus, TLR-2 and TLR-9 receptor–initiated signal transduction is intact in SLAM/ macrophages. The
collective results obtained were consistent regardless of
whether the macrophages were isolated from SLAM/
C57Bl/6 or SLAM/ BALB/c mice and of the method of
preparation of peritoneal macrophages.
Figure 4. Monoclonal anti-SLAM antibody
regulates IL-6 and IL-12 production by WT
macrophages. IL-12 and IL-6 production by
SLAM/ or SLAM/ C57BL/6 thioglycollateelicited peritoneal macrophages was determined
in response to the anti-SLAM antibody 9D1. 106
peritoneal macrophages from SLAM/ or
SLAM/ C57BL/6 mice were treated for 24 h
with 9D1 at the concentrations indicated. To each
well, a rat anti–mouse IgG1 isotype control antibody was added (BD Biosciences) in a concentration range from 10 to 0 g/ml, resulting in a
final concentration of 10 g/ml Ig in each experimental point. Supernatants were collected and
analyzed for IL-12 p40 (A) or IL-6 (B) by ELISA.
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Two sets of experiments showed that there is no global
defect in the SLAM/ macrophages. First, SLAM/ and
WT BALB/c peritoneal macrophages, pulsed with OVA
peptide, were used to induce proliferation of KJ-126
CD4 T cells derived from the DO11.10 mouse, which is
specific for H-2d class II and OVA peptide. SLAM/
BALB/c and WT BALB/c peritoneal macrophages were
equally efficient in stimulating DNA synthesis of DO11.10
CD4 cells (Fig. 3 H). Second, phagocytosis of E. coli F18
bacteria by SLAM/ BALB/c macrophages was intact
(Fig. 3 I). Together, these analyses demonstrate that SLAM
specifically regulates the production of IL-12, TNF-,
NO, and IL-6 upon triggering of TLR-4 by LPS.
To test whether SLAM functions as a coreceptor on the
surface of WT macrophages, the anti–mouse SLAM monoclonal antibody 9D1 (13) was used. As shown in Fig. 4 A,
9D1 induces IL-12 secretion by WT macrophages, whereas
incubation with increasing concentrations of 9D1 negatively interferes with IL-6 production by WT macrophages
(Fig. 4 B). Importantly, SLAM/ BALB/c macrophages
served as negative controls, thus excluding the possibility
that anti-SLAM affected IL-6 and IL-12 production by
nonspecific Fc receptor binding. Furthermore, an isotype
control antibody was included in these experiments.
Results of the antibody experiments support the notion
that SLAM confers a positive signal to LPS-induced IL-12
production by macrophages. The antibody data combined
with the SLAM/ macrophage studies also support the hypothesis that SLAM negatively controls IL-6 production. Together, the in vitro and in vivo data demonstrate that in both
SLAM/ C57BL/6 and SLAM/ BALB/c mice, macrophage functions related to SLAM signaling are impaired.
SLAM/ C57Bl/6 Mice Are Susceptible to Infection with L.
major. To determine the in vivo effect of the absence of
the coreceptor SLAM, SLAM/ BALB/c mice were infected with L. major. Initial foodpad lesions in BALB/c
mice in response to the parasite L. major result in part from
a rapid response by CD4 T and NKT cells producing
large amounts of IL-4 early after infection (24). In spite of
the reduced in vitro IL-4 production by SLAM/ T cells
(Fig. S2), SLAM/ BALB/c mice responded to the parasite in the same manner as WT BALB/c mice (Fig. 5 A).
Thus, a minimal in vivo IL-4 production during the initial
phase of infection of SLAM/ BALB/c mice with L. major
appears to be sufficient for the typical BALB/c response.
The WT level of IL-4 production by the SLAM/ NKT
cells (Fig. 2 E), is likely to be a source of this key cytokine.
By contrast, the size of the footpad lesions in the SAP/
BALB/c mice was significantly smaller than that of the WT
BALB/c mice throughout the course of infection because
of the low level of IL-4 secretion by all CD4 T cells, including NKT cells (9).
C57Bl/6 mice respond differently to infection with the
parasite L. major than BALB/c mice, as C57Bl/6 mice
eventually remove the parasite by mechanisms that involve Th1 cells as well as activated macrophages (24). As
judged by measuring the size of footpad lesions, SLAM/
1261
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Figure 5. SLAM/ C57BL/6 mice are not resistant to infection with
L. major. (A) Response to L. major infection by SLAM/ BALB /c mice.
SLAM/ or SLAM/ BALB/c mice were infected in one footpad with
106 L. major stationary phase promastigotes. The size of footpad lesions of
10 infected mice of each strain was measured until 9 wk after infection
and the change in footpad depth was plotted against time (in weeks).
(B) Response to L. major infection by SLAM/ C57BL/6 mice.
SLAM/ or SLAM/ C57BL/6 mice were infected with L. major as
described in A. 30 mice were used in 3 experiments. A representative
independent experiment with 12 mice is shown. , SLAM/ mice; ,
SLAM/ mice. (C) Response to L. major infection by SAP/ C57BL/6
mice. 10 SAP/ or WT (SAP/) C57Bl/6 mice were infected with L.
major as described in A. , SAP/ mice; , WT SAP/ mice.

C57BL/6 mice did not efficiently heal the infection with
L. major (Fig. 5 B). This impaired ability to clear the parasite was confirmed by increased parasite titers in infected
SLAM/ C57BL/6 mice (log parasite titer, 4.16 1.03),
compared with WT C57BL/6 mice (log parasite titer,
1.82 0.72; P  0.005) at the end of the experiment.
The inability of SLAM/ C57BL/6 mice to heal the L.
major lesions is consistent with defective IL-12 and TNF-
production by SLAM/ macrophages because secretion of

IL-12 and TNF- is known to be required for sustaining the “healing phenotype” in C57BL/6 mice (24–26).
Moreover, the in vitro leishmaniacidal activity of SLAM/
peritoneal macrophages was markedly reduced. SLAM/
C57BL/6 macrophages were less efficient in killing parasites in vitro (73 8% infectivity) than WT macrophages
(37 12%). Because our in vitro studies showed impaired
NO production (Fig. 3), and as NO plays a major role in
the removal of L. major by macrophages (26), the inability
of SLAM/ C57BL/6 mice to combat L. major infection
provides further evidence for a macrophage defect.
Based upon our in vitro CD4 T cell analyses (Fig. 2),
the abnormal response to L. major by SLAM/ C57BL/6
mice was unlikely to have been caused by a defective Th1
response. Indeed, when SLAM/ and WT C57BL/6 T
cells isolated from the lymph nodes of infected animals
were examined at the end of the experiment, both mutant
and WT CD4 cells secreted comparable amounts of IFN-
(SLAM/, 6,905 1,426 pg/ml; WT, 9,213 120 pg/
ml). As expected for C57BL/6 mice (24–26), at the end of
the infection only very low levels of IL-4 (20 pg/ml)
were secreted either by mutant or by WT T cells in
response to L. major antigen. DNA synthesis of these
SLAM/ T cells was similar to that of WT C57BL/6 T
cells. The stimulation index was 6.14 1.41 for SLAM/
T cells (n  12) and 7.2 4.87 for WT T cells (n  12).
Thus, upon infection of C57BL/6 mice with L. major, the
relevant macrophage responses, but not the T cell responses, were affected by the SLAM mutation. This conclusion was indirectly supported by analysis of an L. major
infection of SAP/ C57BL/6 mice, which have a T cell
defect similar to that of the SLAM/ C57BL/6 mice (Fig.
2 D; references 9 and 10) The SAP/ C57BL/6 mice
were able to remove the parasite and heal the footpad lesions with the same kinetics as WT C57BL/6 mice (Fig. 5
C). Taken together, the data strongly support the notion
that the abnormalities observed in macrophages, but not
those found in T cells, account for the impaired responses
by the SLAM/ C57BL/6 mice to infection with L. major.

Discussion
These analyses of SLAM/ T cells demonstrate that
SLAM-induced signal transduction differentially modulates TCR-induced IFN- and IL-4 production. SLAM
negatively interferes with IFN- production in CD8 T
cells and to a lesser extent in CD4 T cells. By contrast,
SLAM augments IL-4 secretion induced by engagement of
TCR on the surface of CD4 T cells. As the absence of
SAP influences TCR responses in a very similar manner, it
appears that SLAM and SAP cooperate toward the same
sets of signals. Thus, the SLAM/SAP receptor–adaptor
complex is one of the few cell surface–signaling units that
contributes to cell fate during terminal differentiation into
Th1 and Th2 cells. Because the adaptor SAP operates as a
control element of signal transduction pathways of at least
six members of the SLAM family of T cell surface recep1262

tors, the less stringent control of IL-4 production in
SLAM/ mice compared with SAP/ mice can be explained by overlapping functions of the other receptors (2).
The notion that SLAM is a coreceptor in TCR-driven
functions was originally developed in studies with antiSLAM antibodies. As stimulation of TCR in the presence
of anti-SLAM antibody results in increased IFN- production (1, 2), both antibody treatment and removal of
the SLAM receptor appear to eliminate the negative costimulatory signal. However, the present data also show
that TCR-induced IL-4 secretion by SLAM-deficient T
cells is impaired, whereas treatment with anti-SLAM has
no effect on IL-4 gene activation (1, 2). It is conceivable
that anti-SLAM interrupts the interaction of SLAM with
its ligand SLAM on a second cell, i.e., APC. It is also conceivable that anti-SLAM causes clustering of SLAM molecules on a T cell, which then brings SLAM clusters in
proximity of the TCR. In general, differences between
antibody effects and findings in knockout mice have been
reported. For example, in the case of the cell surface receptor CD2, anti-CD2 has an effect on T cell functions,
but disruption of the CD2 gene does not have functional
consequences for the T cell (27). Furthermore, anti–
CTLA-4 had been thought at first to have costimulatory
properties until further studies and results with the CTLA4/ T cells showed that the antibody inhibited a negative
signal (28, 29). In addition, triggering a receptor with antibodies can also give different outcomes than the use of a
soluble form of ligand, as shown in studies of SLAM.
Triggering of human SLAM either by its ligand (i.e., FcSLAM) or by anti-SLAM antibody has different outcomes.
Punnonen et al. (30) show that a soluble human SLAM
Ig protein induces responses in T and B cells that differ
dramatically from the responses induced by anti–human
SLAM monoclonal antibodies.
The signal transduction events that are initiated by engagement of SLAM use a pathway that leads to activation
of the Ser/Thr kinase Akt (23). Furthermore, signal transduction by SLAM is in part governed by SAP, which is an
adaptor that links the src kinase FynT to the SLAM receptor. SAP appears to bind to the SH3 domain of FynT and it
therefore directly couples and activates FynT to SLAM
(5–7, 31). In addition, overexpression experiments and
analysis of Fyn/ T cells clearly show that SLAM can be
phosphorylated by other src kinases in a SAP-dependent
manner (31). But how SLAM-induced or SAP-controlled
signaling networks are involved in activation of the IL-4
gene is unknown. Because the SLAM- and SAP-controlled
signal transduction pathways do not involve Ca2-dependent mechanisms (Fig. S5), a further dissection of the molecular underpinnings of the role of SLAM or SAP in governing TCR-induced IL-4 production is required.
The role of SLAM as a TLR-4 coreceptor on the surface
of macrophages was established by experiments with LPS
and SLAM/ BALB/c and SLAM/ C57BL/6 macrophages as well as by the use of an anti-SLAM monoclonal
antibody. In response to antibody, IL-12 secretion by puri-
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fied macrophages is induced and IL-6 production is impaired. In the SLAM/ macrophage, LPS induced IL-12
and TNF secretion is impaired and SLAM/ macrophages
overproduce IL-6 even in the absence of any extraneous
stimuli. The two types of responses suggest that SLAM
signaling negatively influences IL-6 production and augments IL-12 secretion. Moreover, both SLAM/ BALB/c
and SLAM/ C57BL/6 macrophages produce reduced
amounts of NO upon stimulation with LPS.
The inefficiency of SLAM/ C57BL/6 macrophages in
killing L. major is consistent with both an impaired NO production and reduced levels of IL-12 and TNF production.
The signaling pathways involved in the coreceptor function
of SLAM with respect to production of IL-12, TNF-, and
NO in response to LPS is currently being explored.
Infection of SLAM/ BALB/c mice with L. major followed the typical BALB/c response, i.e., uncontrolled increase of footpad swelling. The WT level of IL-4 production by the SLAM/ NKT cells and the residual in vivo
IL-4 production are undoubtedly factors in the early responses to the parasite (24–26). We speculate that a contribution of the macrophage defect of SLAM/ BALB/c
mice may also contribute to the sustained response. By contrast, as previously reported (9), the size of the footpad lesions in the SAP/ BALB/c mice was significantly smaller
than that of the WT BALB/c mice throughout the course
of infection because of the low level of IL-4 secretion by all
CD4 T cells and the absence of a macrophage defect.
The use of SLAM as one of the two receptors for measles virus suggests that SLAM functions are required for
both innate and acquired immune responses. Although
engagement of the measles virus receptors CD46 and
SLAM on dendritic cells or macrophages has been linked
to regulation of IL-12 production, the role of IL-12 in the
immunosuppression is not understood. As measles virus–
induced immune suppression has a strong T cell component as well (32–34), further studies to elucidate the molecular mechanisms of SLAM signaling in T cells and
APCs are needed. In that regard, the availability of welldefined transgenic mouse strains that correctly express human SLAM on a SLAM/ background will be invaluable
for the study of aberrant immune responses to measles virus. Thus, the availability of SLAM-deficient mice will allow for studies that provide a better understanding of the
role of innate and adaptive immune responses to both parasites and viruses.
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